It is important to understand the magnitude and distribution of the economic burden of prescription opioid overdose, abuse, and dependence to inform clinical practice, research, and other decision makers. Decision makers choosing approaches to address this epidemic need cost information to evaluate the cost effectiveness of their choices.
T he adverse health effects of the misuse of prescription opioids, including abuse, dependence, and overdose are a well-documented public health problem. 1 Fatal prescription drug overdoses have been described as an epidemic by the US Centers for Disease Control and Prevention. 2 Prescription opioids account for approximately 70% of fatal prescription drug overdoses. 3, 4 Decision makers at both the federal and state levels have responded to the epidemic with several strategies aimed at reducing the burden of the epidemic. For example, in 2011 the US Office of National Drug Control Policy issued a set of recommendations that, in part, call for all states to have functional prescription drug monitoring programs (PDMPs), and encourages federal agencies such as the Veterans Administration to share data with state PDMPs when legally permitted to do so. 5 Policies such as these face a difficult task in addressing the overdose epidemic while balancing the care of patients who need treatment for pain. Also, decision makers in government and the health care sector face financial constraints that require strategies that are cost efficient as well as effective, while also considering the resource use for addressing other social and health problems.
An essential component in identifying prevention strategies that are cost-effective is understanding the economic burden produced by the adverse health outcomes. Previous researchers have estimated the overall societal impact of prescription opioid misuse. 6, 7 Other studies have examined specific components of the overall issue of opioid misuse, such as the cost of poisonings, nonmedical use, 8 and abuse and workplace absenteeism. 9 Most recently, Birnbaum et al 10 estimated the overall societal impact of prescription opioid abuse, dependence, and misuse in the United States to be $55.7 billion in 2007. Since that year, however, the epidemic has continued to progress. From 2007 to 2013, the annual number of prescription opioid overdose deaths has increased by over 1800 cases, 3 and the annual number of persons who abuse or are dependent on prescription opioids has increased by over 200,000 persons. 11 In this study, we present updated estimates of the economic burden of prescription opioid overdose, abuse, and dependence for 2013 using the most recently available data. We also incorporate more comprehensive health care spending data than previous studies, and we use recently updated methods for valuing the loss of productivity (both through employment and household activities) for fatal and nonfatal cases.
METHODS

Overview
In this study, we calculated cost estimates of prescription opioid overdose, abuse, and dependence based on the incidence of overdose deaths and the prevalence of prescription opioid abuse and dependence for calendar year 2013. We considered a societal perspective, which means we considered both the cost for persons experiencing overdose or abuse/dependence, and costs incurred by society in general, such as criminal justice-related costs. The cost components that considered were health care and substance abuse treatment cost, criminal justice cost, and lost productivity. Costs calculated for abuse and dependence are annual costs, while costs for fatal cases are lifetime costs discounted to 2013 present value at a rate of 3%. We used the most recently available year of data for all cost components. When the most recent year of data available was earlier than 2013, costs were inflation-adjusted to 2013 dollars.
Our measure of incidence of prescription opioid overdose deaths in 2013 came from the CDC WONDER database, which records all deaths reported in the United States National Vital Statistics System. 3 Cases were identified using the multiple cause of death ICD-10 codes (T40.2-T40.4), which identify deaths across all intents (unintentional, intentional, and undetermined). Prevalence of prescription opioid abuse and dependence was measured using the 2013 National Survey on Drug Use and Health (NSDUH). The NSDUH is a nationally representative sample of the US civilian noninstitutionalized population ages 12 and older. The survey collects detailed information on substance use, including a questionnaire that can identify abuse and dependence based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 12 definition for a variety of substances, including prescription opioids. The survey also collects detailed data on health insurance coverage during the year, and basic demographic information such as sex and age. This information was used in assigning health care costs and lost productivity costs to abuse/dependence cases, as described in more detail below. Survey weights were included in the data that allow for estimation of nationally representative population totals for cases of substance abuse and dependence. Details of all calculations presented below may be found in the electronic appendix (Supplemental Digital Content 1, http://links. lww.com/MLR/B261) that accompanies this study.
Health Care Costs
A matched case-control design was used to estimate the impact of prescription opioid abuse diagnoses on health care spending. This design was implemented using the deidentified Truven Health MarketScan Research Databases for commercial, Medicaid, and Medicare health plan enrollees. The MarketScan data capture person-specific utilization, expenditures, and enrollment across inpatient, outpatient, and prescription drug claims. The commercial database includes private-sector health data from approximately 100 different insurance companies. The Medicare database contains claims for Medicare-eligible retirees with employersponsored Medicare Supplemental plans, and include expenditures buy both Medicare and supplemental coverage. The MarketScan Medicaid Database contains the pooled health care experience of approximately 7 million Medicaid enrollees from 11 geographically dispersed states. The Medicaid data does not identify the states included to preserve confidentiality. As the estimation strategy requires the comparison of expenditures at an individual level, the analysis excludes those in capitated payment plans.
Prescription opioid abuse and dependence cases were identified using previously described methodology. 13 Diagnosed commercial, Medicare, and Medicaid cases were identified as patients with Z1 diagnosis for opioid abuse or dependence during the third quarter of 2011 through the fourth quarter of 2012, defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for opioid abuse, dependence or overdose [304.0X (opioid type dependence), 304.7X (combinations of opioid type dependence with any other drug dependence), 305.5X (nondependent opioid abuse), 965.00 (poisoning by opium (alkaloids) unspecified), 965.02 (poisoning by methadone), and 965.09 (poisoning by other opiates and related narcotics)]. It is not possible to distinguish prescription opioid dependence from heroin dependence with the ICD-9 codes. The implications of this limitation of the data for our results will be discussed below.
All patients were continuously eligible with noncapitated plan coverage during the 18-month study period. The 18-month study period consisted of a 12-month observation period with first diagnosis as the index date, and a 6-month baseline period preceding the observation period that was used for propensity score matching. For example, if patient A's first abuse diagnosis date was February 1, 2012 then this date was considered the index date for this patient. Then the 18-month study period included the 6-month baseline period (August 1, 2011-January 31, 2012) before the index date and the 12-month period (February 1, 2012-January 31, 2013) after the index date. For the comparison patients, the index date was assigned as the date of a random medical claim, and the data were then organized around this date by the same method.
To account for baseline differences in demographics, comorbidities, and health care resource use, abusers were matched 1:1 to comparison patients based on propensity scores estimated using a logistic regression model for all study patients. For commercial and Medicare analyses, the regression model included age, sex (male/female), baseline health care costs, Charlson comorbidity index, region of patient residence (Northeast, North Central, South, West), and plan type (eg, Exclusive Provider Organization, Health Maintenance Organization, Non-Capitated Point-of-Service, etc.) as independent variables. Because Medicaid has slightly different variables, the logistic regression used following variables: age, sex (male/ female), race (white, black, Hispanic, and other), baseline health care costs, Charlson comorbidity index, Medicare eligibility, basis of eligibility (eg, low income child), and plan type (eg, basic/major medical, comprehensive, Exclusive Provider Organization, Health Maintenance Organization, Preferred Provider Organization, etc.). The cost was total health care cost including inpatient and outpatient care and all prescription drugs. Health care costs in the 12-month observation period were compared between abuse or dependence cases and matched comparison patients to determine the excess annual per patient health care costs. Nonlinear regression models were estimated to account for the skewed nature of the health care expenditure data (gamma family with log link), with expenditures as the dependent variable and an indicator for diagnosed or control group as the independent variable. 14 Excess medical and drug per-patient costs were then multiplied by the relevant number of opioid abuse patients derived from the NSDUH for each insurance coverage category reported in the survey data (Private, Medicare, Medicaid, CHAMPUS/VA, other, and uninsured). CHAMPUS/ VA and other categories were assigned costs for private coverage. The uninsured were assigned 50% of the cost of private insurance, based on reports that show this to be the typical ratio of spending for the uninsured population. 15 While the estimation described above will account for the cost of health services reimbursed by insurance plans for those diagnosed with opioid use disorder, there are other sources of payment for substance abuse treatment that are important to measure. Substance abuse treatment costs that were not paid by health insurance (such as public programs like SAMSHA block grants and private foundation funding) were calculated by identifying non-insurance-based federal, state, local, and private expenditures on substance abuse treatment. 11 These costs were multiplied by the share of drug abuse and dependence cases associated with prescription opioids in the 2013 NSDUH.
Criminal Justice Costs
We followed an apportionment approach previously described 10 to update criminal justice costs to 2013. 16 This method consists of using reported criminal justice spending for drug crimes and multiplying that number by the share of drug abuse and dependence cases represented by prescription opioids from NSDUH. The criminal justice costs consisted of 4 components: (1) police protection, (2) legal and adjudication, (3) correctional facilities, and (4) property lost due to crimes. We obtained spending data on police protection, legal and adjudication activities, and correctional facilities from the Justice Expenditure and Employment Extracts, 2012-Preliminary 17 and data on property lost due to crimes from the Crime in the United States 2012. 18 We replicated the calculation procedures by Birnbaum and colleagues to estimate the proportions of these 3 components attributable to prescription opioid abuse or dependence: the ratio of arrests for the components of police protection and legal and adjudication, 18-21 the ratio of incarcerations for the correctional facilities component, 22 and the ratio for the component of property lost due to crimes.
Lost Productivity Costs
We considered lost productivity costs from: (1) premature death from prescription opioid abuse or dependence, (2) reduced productive hours for abuse/dependence, and (3) incarceration. We estimated the cost of fatal opioid abuse or dependence by entering the number of prescription opioid overdose deaths in 2013 into the Cost of Injury Reports application under CDC's WISQARS (Web-based Injury Statistics Query and Reporting System) cost module. 23 The WISQARS cost module estimates the lost productivity of a fatal injury based on the sex and age of the decedent and the mechanism of injury. Cost are assigned based on the earnings expected for a person of the decedent's sex and age over the remaining expected lifespan. We used the cost estimate for those that died from poisonings, for all intents.
In calculating lost productivity for abuse and dependence, we used an approach that values the loss of "productive hours." Productive hours are any time that is spent in paid employment or household productivity. The measure of production value used estimated the average time spent in employment and household production and estimated the value (including fringe benefits) of this time by age and sex category. This value then was multiplied by the percentage reduction in productivity attributable to drug abuse/dependence (17% for males and 18% for females 24 ), and finally summed over values across all sex and age groups. The prevalence of prescription opioid abuse/dependence cases for each sex and age group were tabulated from the 2013 NSDUH, then multiplied that by the corresponding per person annual production value of US population, 25 which was inflated to 2013 dollars.
To calculate lost productivity due to incarceration, we first used the numbers of inmates incarcerated for crimes attributed to prescription opioid abuse/dependence at federal, state, and local levels in 2013. After estimating the numbers of federal, state, and local inmates incarcerated for crimes attributed to prescription opioid abuse or dependence, we then multiplied those numbers by the per person annual production value of the US population inflated to 2013 dollars.
Finally, a sensitivity analysis for all major cost categories was conducted. This was done by calculating the cost numbers at the endpoints of the 95% confidence interval of both the prevalence of prescription opioid abuse and dependence and the number of prescription opioid deaths. Table 1 reports the prevalence of prescription opioid abuse and dependence, and the number of fatal overdoses from prescription opioids in 2013. Almost 2 million people are estimated to meet the DSM-IV criteria for abuse and dependence, and over 16,000 died from prescription opioid overdoses. Both of these numbers represent a substantial increase from the most recently published comprehensive cost estimates from 2007, with the number of fatal cases over 1800 higher, and the prevalence of abuse and dependence increased by approximately 200,000 persons. Table 2 reports the estimates of annual health care cost differences for patients diagnosed with opioid abuse or dependence and their matched comparisons. The cost differences for all 3 types of insurance are large and statistically significant. Medicare has the largest cost difference at over $17,000. Private insurance has a cost increase of $15,500, and Medicaid is over $13,700. Full regressions results for the propensity score matching and health care expenditure regressions are available in the electronic appendix (Supplemental Digital Content 2, http://links.lww.com/MLR/B262).
RESULTS
The aggregate costs associated with fatal overdose and abuse/dependence cases, and the range of estimates based on the variation in estimated abuse, dependence, and overdose outcomes, are reported in Table 3 . The aggregate cost for these prescription opioid-related overdose, abuse, and dependence was over $78.5 ($70.1-$87.3) billion. Almost two thirds of these costs were related to health care, substance abuse treatment, and lost productivity for nonfatal cases ( The aggregate costs demonstrate the substantial amount of the economic burden that is borne by federal, state, and local government. Over 14% of the cost is funded by public health insurance programs (Medicare, Medicaid, and Champus/VA), and 3.2% is from additional government sources for substance abuse treatment. Almost all of the criminal justice-related costs (96%, or $7.3 of $7.7 billion) goes to activities directly funded by state and local government. Taken together, this means that almost 25% of the aggregate economic burden is funded by public sources. In addition, some portion of the lost earnings will be borne by the public sector in the form of forgone tax revenue.
DISCUSSION
The analysis presented here is subject to several limitations. In some cases, these limitations can help identify areas for further research that will improve our understanding of the impact of the prescription opioid overdose epidemic. For example, our estimates of nonfatal costs are based on the prevalence of abuse and dependence. Ideally, the economic burden of an adverse health outcome would be estimated by calculating the lifetime cost of the conditionthat is, observing the condition from its onset until it ends. Then, the total value of preventing the condition from occurring would be known. At the present time though, information in the research literature about the natural history of opioid misuse does not allow for such a calculation, and surveillance systems are not in place to adequately measure the incidence of the condition in the population. Our health care cost estimates used the definition of opioid abuse and dependence identified by ICD-9 diagnosis codes. This definition does not differentiate between prescription opioids and heroin. Because we are interested in the difference in health care spending between those with abuse or dependence and those without, this will bias our results if prescription opioid abuse or dependence and heroin abuse or dependence have different effects on health care spending. On the basis of responses to the NSDUH, prescription opioid abuse and dependence is far more common than for heroin. In 2013, an estimated 1.9 million people reported prescription opioid abuse or dependence, whereas 517,000 reported heroin abuse or dependence (with some reporting both). If diagnosed opioid abuse/dependence follows a pattern similar to NSDUH responses and heroin and prescription opioid users are equally likely to be treated, the effect on our estimates should be mitigated.
Finally, we did not attempt to attribute costs to specific drugs if multiple types of drug abuse were reported. This could bias our results if the health care cost impact of abuse and dependence is different between prescription opioids and heroin, or if abuse of prescription opioids alone has a different effect from abuse of multiple drugs. We are also unable to account for the impact of diversion of drugs for nonmedical use. Future research could analyze whether this is the case using data that allows for these different sources of abuse and dependence to be identified.
We also estimated the per case health care cost impact using a convenience sample of persons enrolled in commercial insurance plans, Medicare plans with an employersponsored supplemental plan, and subset of state Medicaid plans. The populations covered by these plans are not representative of the US population, and also may not be representative of the populations most at risk for opioid overdose, abuse, or dependence. For example, many people receiving Social Security disability payments are covered by both Medicare and Medicaid. In our analysis, health care spending was only measured for 1 health insurance plan for each dependent person. In the case of these "dual eligible" patients, our health care cost estimates will be too low. We also depended on medical diagnosis of abuse and dependence, which could underreport the true rate.
Finally, it is extremely difficult to measure all costs to society from an epidemic. In this case, there are many costs we were unable to measure, such as the reduction in quality of life of those who are dependent. These impacts are substantial, with a previous study finding a quality-adjusted life year reduction of approximately 50%. 26 We also cannot account for the pain and suffering of family members who have lost loved ones due to fatal overdoses. The costs that we can identify, however, do help increase our understanding of the impact of the epidemic.
The economic burden estimates presented here help to quantify some of the adverse health impacts associated with prescription opioids. In the ideal case, decision makers could use these estimates when weighing the benefits and risks of using opioids to treat pain, and evaluating prevention measures to reduce harmful use. However, at the present time a full accounting of both the benefits and costs of prescription opioid use is not available.
The results presented here are also helpful in understanding the distribution of the economic burden. A large share of the cost 
